[HTML][HTML] Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy
M Sereno, G Gutiérrez-Gutiérrez, JM Rubio… - BMC cancer, 2017 - Springer
Background Oxaliplatin is a chemotherapy agent active against digestive tumors. Peripheral
neuropathy is one of the most important dose-limiting toxicity of this drug. It occurs in around …
neuropathy is one of the most important dose-limiting toxicity of this drug. It occurs in around …
Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy
M Sereno, G Gutiérrez Gutiérrez, J Moreno Rubio… - 2017 - docta.ucm.es
Background: Oxaliplatin is a chemotherapy agent active against digestive tumors. Peripheral
neuropathy is one of the most important dose-limiting toxicity of this drug. It occurs in around …
neuropathy is one of the most important dose-limiting toxicity of this drug. It occurs in around …
Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy
M Sereno, G Gutierrez-Gutierrez, JM Rubio… - BMC …, 2017 - search.proquest.com
Background Oxaliplatin is a chemotherapy agent active against digestive tumors. Peripheral
neuropathy is one of the most important dose-limiting toxicity of this drug. It occurs in around …
neuropathy is one of the most important dose-limiting toxicity of this drug. It occurs in around …
[HTML][HTML] Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy
M Sereno, G Gutiérrez-Gutiérrez, JM Rubio… - BMC Cancer, 2017 - ncbi.nlm.nih.gov
Background Oxaliplatin is a chemotherapy agent active against digestive tumors. Peripheral
neuropathy is one of the most important dose-limiting toxicity of this drug. It occurs in around …
neuropathy is one of the most important dose-limiting toxicity of this drug. It occurs in around …
[HTML][HTML] Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy
M Sereno, G Gutiérrez-Gutiérrez… - BMC …, 2017 - bmccancer.biomedcentral.com
Oxaliplatin is a chemotherapy agent active against digestive tumors. Peripheral neuropathy
is one of the most important dose-limiting toxicity of this drug. It occurs in around 60–80% of …
is one of the most important dose-limiting toxicity of this drug. It occurs in around 60–80% of …
[引用][C] Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy
M Sereno, G Gutierrez-Gutierrez, JM Rubio… - BMC Cancer …, 2017 - jglobal.jst.go.jp
J Clin Oncol; Phase III randomized, placebo-controlled, double-blind study of intravenous
calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity …
calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity …
Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy.
M Sereno, G Gutiérrez-Gutiérrez, JM Rubio… - BMC Cancer, 2017 - europepmc.org
Background Oxaliplatin is a chemotherapy agent active against digestive tumors. Peripheral
neuropathy is one of the most important dose-limiting toxicity of this drug. It occurs in around …
neuropathy is one of the most important dose-limiting toxicity of this drug. It occurs in around …
Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy
M Sereno, G Gutiérrez-Gutiérrez, J Moreno Rubio… - BMC …, 2017 - repositorio.uam.es
Background: Oxaliplatin is a chemotherapy agent active against digestive tumors. Peripheral
neuropathy is one of the most important dose-limiting toxicity of this drug. It occurs in around …
neuropathy is one of the most important dose-limiting toxicity of this drug. It occurs in around …
Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy
M Sereno, G Gutiérrez-Gutiérrez, JM Rubio… - BMC …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Oxaliplatin is a chemotherapy agent active against digestive tumors. Peripheral
neuropathy is one of the most important dose-limiting toxicity of this drug. It occurs in around …
neuropathy is one of the most important dose-limiting toxicity of this drug. It occurs in around …
Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy
M Sereno, G Gutinrrez-Gutinrrez, JM Rubio… - BMC Cancer, 2017 - go.gale.com
Background Oxaliplatin is a chemotherapy agent active against digestive tumors. Peripheral
neuropathy is one of the most important dose-limiting toxicity of this drug. It occurs in around …
neuropathy is one of the most important dose-limiting toxicity of this drug. It occurs in around …